• FingerMotion Inc.’s proprietary PigeonHole Integration System works in tandem with the three major Chinese telecom giants, providing a large potential for growth and customer reach, especially since the market is predicted to go unchanged despite the uncertainty of economic conditions brought on by the pandemic
• China Mobile is looking at potential A-share listings, whereas China Telecom has already announced the intention of listing with the Shanghai Stock Exchange with the issuance of 12 billion shares, with profits set to help fund the 5G industrial Internet project
• Using the data collected from these telecom giants, FingerMotion will be able to fine-tune its current offering while developing other products

FingerMotion (OTCQX: FNGR) is a technology company, constantly evolving its core competencies in mobile payment and recharge platform solutions for mainland China. FingerMotion is positioned to capitalize on the telecom market growth and opportunities, as well as its partnership with the country’s telecommunications giants, through the company’s proprietary platform and technology. It is one of only a few companies in China with access to wholesale rechargeable minutes from China’s largest mobile phone providers that can be resold to consumers.

One of China’s top mobile providers, China Mobile, is currently looking into the possibility of an A-share listing. Another one of China’s state-owned carriers, China Telecom, has already announced plans to list on the Shanghai Stock Exchange (“SSE”). The plan proposed by China Telecom will be to issue as many as 12 billion shares on the mainland China exchange – pricing is currently unknown, but it could come at a large premium. China Telecom plans to use the listing proceeds to construct a 5G industrial Internet project, boosting its cloud network. The Shanghai listing plan is currently waiting for approval by the Chinese Securities Regulatory Commission.

FingerMotion’s telecom products and services include a universal exchange platform, which has been named “PigeonHole Integration System (‘PIS’),” offering seamless integration between telecom operators and online stores.

PIS offers consumers top-up and recharge services, data plans, mobile phones, loyalty points redemption, and subscription plans. All transactions are reliable and secure, featuring real-time reconciliation and simple integration for partners with efficient settlements.

According to Research and Markets China Telecoms Report – 2020-2025, the Chinese telecommunications industry is expected to remain steady even with the political uncertainties and uncertain economic outlooks due to the COVID-19 pandemic. The report stated that the growing mobile phone penetration and high-fixed broadband among households would fuel the growth over the next five years (https://ibn.fm/lymhT).

FingerMotion is currently working to strengthen the existing and strategic partnerships it has with the Chinese telecommunication giants. Through the partnerships, the company will gain access to comprehensive and unbiased telco data on a real-time, unimpeded basis while covering a massive population. FingerMotion will then transform and integrate with its own proprietary collection for more effective and efficient capitalization and delivery using this data.

For more information, visit the company’s website at www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom https://ibn.fm/FNGR

• TAAT enters agreement for GGE to be exclusive distributor for flagship product in the United Kingdom and Ireland
• “It is an exciting development for us to have received our first purchase order for overseas shipment,” says CEO
• TAAT could realize competitive advantage based on relatively high retail cost of tobacco cigarettes in the UK and Ireland

TAAT(TM) Global Alternatives (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) has entered into a letter of intent with Green Global Earth Ltd. (“GGE”). The agreement calls for GGE to be the exclusive distributor for TAAT(TM)’s flagship product in the United Kingdom and Ireland. In addition, Green Global Earth placed a €100,000 purchase order for an initial supply of TAAT’s Original, Smooth and Menthol tobacco-free, nicotine-free alternative (https://ibn.fm/zazFp). “Expansion launches in the CPG category need to be conducted passively, so as to ensure the product is optimally positioned in its new markets,” said TAAT CEO Setti Coscarella. “Although we believe TAAT is generally relevant to those out of the more than one billion tobacco users worldwide who aspire to leave nicotine behind, entering a new region is a complex task based on the nuances of each market in economic and competitive terms, as well as the general attitudes towards alternatives to products such as tobacco cigarettes. “We are pleased to have an accomplished and well-connected wholesaler such as GGE on our side,” he continued. “It is an exciting development for us to have received our first purchase order for overseas shipment as we seek to commercialize TAAT internationally for the first time.” In the announcement, TAAT noted that it could realize a competitive advantage based on the relatively high retail cost of tobacco cigarettes in the UK and Ireland. The company noted that, based on data from the World Health Organization (“WHO”), the prices of the most-sold brand of cigarettes (pack of 20) in international dollars were $13.58 in the United Kingdom and $14.95 in Ireland, compared to $6.86 in the United States. With a 14.1% tobacco use incidence rate among the United Kingdom’s legal-aged population and an incidence rate of approximately 20% among adults in Ireland, TAAT sees exciting opportunities in these markets.The cost advantage combined with the incidence rate of smokers, many whom are eagerly seeking for a nicotine-free, tobacco-free alternative, place the company — and its game-changing product — in a strong position. Based on the distribution agreement between TAAT and GGE, the TAAT smoking alternative will be available through GGE’s existing wholesale network. Targeting adult-aged smokers, the rollout of the new program will capitalize on the fact that TAAT’s Beyond Tobacco(TM) experience closely mimics every sensory element of smoking a tobacco cigarette. TAAT has captured the experience through packaging, scents, crackling sounds, a tobacco taste and even the motor habits, such as hand to mouth and flicking of ashes. The success of TAAT seems to prove that smokers aren’t just reaching for cigarettes for the nicotine; rather, many enjoy the smoking ritual and experience. TAAT offers an alternative experience without compromise. TAAT Lifestyle and Wellness has developed TAAT, a tobacco-free and nicotine-free alternative to traditional cigarettes available in Original, Smooth and Menthol varieties. TAAT’s base material is Beyond Tobacco, a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with Big Tobacco pedigree, TAAT was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion global tobacco industry. For more information, visit the company’s websites at www.TryTAAT.com and www.TAATGlobal.com. NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at https://ibn.fm/TOBAF

• First order marks a significant milestone as Veterans Affairs runs the largest integrated healthcare system in the country
• BRSF hopes the relationship will bring cutting-edge brain diagnostics to a nationwide network of veterans’ health care

Brain Scientific (OTCQB: BRSF), a commercial-stage, neurology-focused medical device and software company, has announced the start of working with the U.S. Department of Veterans Affairs – VA Medical Centers, which placed the first purchase order of NeuroCap(TM) for one of its hospitals (https://ibn.fm/p3rw0). This move represents a significant milestone because the U.S. Department of Veterans Affairs runs the country’s largest integrated healthcare system. “Our team at Brain Scientific is proud to start what it hopes will be a long-term relationship to serve patient needs at VA Medical Centers and do our part to help reduce risk factors for both patients and staff. Our disposable EEG NeuroCap diminishes the potential for cross-contamination, HAI, and exposure for staff members and patients. Sanitation is a major concern for hospitals and is even more crucial in COVID-19 times as neurodiagnostic teams are urged to find alternatives to reusable products,” said Amy Griffith, vice president of strategy and business development for Brain Scientific. NeuroCap is BRSF’s flagship product, a pre-gelled disposable EEG headset targeting the growing demand for better yet cost-efficient brain monitoring. The need for this disposable and portable device is especially pronounced in the current pandemic environment, which has seen an increasing demand for EEG testing. Since more than 80% of hospitalized COVID-19 patients present with neurological symptoms, rapid EEG testing is becoming critical. This is where Brain Scientific’s NeuroCap enters the picture. Designed for quick application (video of the NeuroCap setup is available here) while also allowing for minimal exposure to patients, NeuroCap appears to be a perfect fit for the current environment where medical professionals are facing a contagious virus. The traditional bulky EEG equipment is complicated to clean between uses and is cumbersome to apply. Even after cleaning, microscopic traces of tissue debris and bacteria may remain on reusable EEG electrodes. This is where NeuroCap makes a difference. Designed for single use, this disposable device helps ensure that the virus is not spread through equipment. The innovative headset also contributes to limiting person-to-person exposure because it is applied quickly and effortlessly, decreasing virus transmission potential between medical staff and patient. Aligned with the international system, NeuroCap features 19 channels and 22 electrodes to produce high-quality study results. Also, NeuroCap is compatible with most existing EEG amplifiers on the market. With this first VA order, Brain Scientific brings this revolutionary brain diagnostics technology to Veterans Health Care, the nation’s most extensive health-care system. Veterans Health Care provides care at 1,255 health-care facilities, including 170 VA Medical Centers and 1,074 outpatient sites that serve more than 9 million veterans (https://ibn.fm/bEdHT). Committed to developing cutting-edge technologies to revolutionize brain diagnostics, Brain Scientific appears to be on the right track to tackle some of neurology’s most pressing diagnostics challenges and narrow the widening gap of accessibility to neurological care across the country. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Company committed to building presence in U.S. and Europe to advance mission of improving mental health care
• New appointments will strengthen Cybin’s development and clinical operations globally, solidify position within the industry
• New leaders bring broad experience, deep insight to their new roles

Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, recently made key senior-management changes designed to provide the company with added insight and expertise in the expansion of its development and clinical operations in the United States and Europe (https://ibn.fm/FsF0L). The appointments, which are effective immediately, call for Alexander Belser, PhD, to serve as chief clinical officer and Aaron Bartlone to serve as chief operating officer.

“We are committed to building our presence both in the United States and in Europe to advance our mission of improving mental health care through therapeutic development programs and innovative drug-delivery systems,” said Cybin CEO Doug Drysdale. “These appointments will serve to strengthen our development and clinical operations globally and solidify Cybin’s position within the industry. Alex and Aaron bring deep clinical, commercial, and regulatory expertise that will serve to broaden our management and scientific leadership teams. We look forward to their contributions as we pursue increased visibility across these additional markets.”

An accomplished biopharmaceutical executive with a proven track record across numerous therapeutic and functional areas, Bartlone brings impressive quality assurance, regulatory affairs, product development, compliance, and commercial operation experience to his new role. Prior to joining Cybin, Bartlone served as both president and managing director for AB Dynamix LLC. In those roles, he oversaw the development of customized and innovative quality-management systems, regulatory strategies, and supply chains for developing pharmaceutical, biotechnology, and medical-device companies.

Bartlone has also worked at UCB Inc., a global pharmaceutical company, and Eli Lilly. He has developed global teams of more than 1,000 colleagues in 50 different countries and has successfully driven more than 25 small and large molecular therapies and drug-device combination products to the global marketplace.

A well-known leader in the field of psychedelic research, Belser has invaluable insight and expertise as an investigator on NYU and Yale University clinical trials of psilocybin and MDMA designed to treat depression, anxiety, substance use, obsessive-compulsive disorder, post-traumatic stress disorder, and end-of-life distress. A former chief clinical officer at Adelia Therapeutics, Belser directed the clinical program investigating tryptamines and phenethylamines for a variety of treatment indications.

In addition, Belser is the founding president of Nautilus Sanctuary, the first nonprofit center for psychedelic medicine in the Eastern United States, and is a recognized expert on psychedelic medicine, having authored a dozen peer-reviewed publications and delivered more than 50 lectures, presentations, and grand rounds on psychedelic topics.

In addition, Cybin also noted that cofounder and former COO Paul Glavine will assume the role of chief growth officer and John Kanakis, cofounder and former SVP of business development, will assume the role of chief business officer.

“Paul and John’s extensive entrepreneurial experience was instrumental in shaping the initial formation of Cybin and the company’s subsequent emergence as a leader within the psychedelics space,” Drysdale stated. “Their deep commitment to Cybin’s mission will continue as they assume these new roles and will allow them to further accelerate business-development and investor-awareness initiatives. We believe these appointments are an important step in taking Cybin to the next level.”

Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches, and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• GLDFF closes on majority ownership of Fifth & Root Inc.
• The acquisition of these distribution channels “greatly increases the company’s visibility and reach,” says CEO
• Fifth & Root brand are ideal match for Golden Leaf and its commitment to produce variety of products for new users as well as seasoned customers

In another move designed to advance its Crawl, Walk, Run strategy, Golden Leaf Holdings (CSE: GLH) (OTCQB: GLDFF) has announced the closing of its previously announced majority ownership purchase of Fifth & Root Inc., a nationally recognized CBD skincare brand based in California (https://ibn.fm/iOdyV). Golden Leaf is a premier, consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution of high-quality cannabis. “The acquisition of these distribution channels greatly increases the company’s visibility and reach, and continues to advance our Crawl, Walk, Run strategic approach,” said Golden Leaf CEO Jeff Yapp. “As we look forward to the eventual federal legalization of cannabis, Fifth & Root’s commerce platform and partnerships will position the company favorably to capitalize on the evolving marketplace. Fifth & Root, a leader in CBD beauty, offers an exceptional line of clean and innovative products. We’re thrilled to add them to Golden Leaf Holdings’ portfolio of products and look forward to growing this brand within the burgeoning CBD skin-care space.” Designed with a “GenZennial” customer in mind, the Fifth & Root brand is an ideal match for Golden Leaf and its commitment to produce a variety of products for new users as well as seasoned customers for both medical and recreational use, with a focus on optimal health and wellness. Fifth and Root was formulated and designed to capture the “vibe of the innovative and experiential formulas in both branding and packaging,” observed Leilah Mundt, founder of beauty branding and sales agency Crème Collective, which worked on the branding for the line. “The formulas are bright and alive with sophisticated terpene blends that smell incredible, as well as being a proven delivery system for the active ingredients. Our goal was to mirror this in all brand touch points.” Fifth & Root is distinctive in that it is a women-founded company; in addition, its products are created and developed by women scientists and herbalists. From the beginning, the vision was to bring transformative, spell-binding skin care to consumers. The line offers powerful, effective formulations that omit toxins and irritants, including toxic chemicals, synthetics, GMOs, parabens, phthalates, harsh preservatives, skin-stripping sulfates and animal byproducts. Fifth & Root products—there are currently six—are sold in more than 425 retail locations, including national retailers such as Ulta Beauty, Nordstrom, Urban Outfitters, Anthropologie, Revolve and more. In addition, it can be purchased online (https://ibn.fm/xuwJ0). Golden Leaf Holdings is a premier consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, with seven dispensaries in Portland, Oregon. The company is committed to developing a dynamic portfolio built around the recognized brands of Chalice Farms, with a focus on health and wellness. Markets served include Oregon, California, Nevada, and Washington. For more information, visit the company’s website at www.GoldenLeafHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to GLDFF are available in the company’s newsroom at https://ibn.fm/GLDFF

• The Emaginos approach is based on a goal of transforming K-12 public schools to a model composed of integrated proven best practices
• Young people are a source of creativity, innovation, and invention that will drive the economy
• The K-12 public education system in this country is a broken national treasure

Walt Disney has been quoted as saying, “Our greatest national resource is the minds of our children.” He’s not alone in that philosophy. The team at Emaginos has built a new educational approach based on the goal of transforming K-12 public schools to a model composed of integrated proven best practices and aimed at developing America’s greatest natural resource – its children “The only truly renewable resource we have in our country today is our students,” says Dr. Keith Larick, who served as superintendent of the Tracy Unified School District in Tracy, California, for years before starting Emaginos (https://ibn.fm/HjaNU). “Those young people who attend our elementary, middle, high schools, colleges and universities are the source of creativity, innovation and invention that will drive our economy and become guardians of our democracy. To thrive and grow, they must have a learning environment that provides a foundation of basic skills, is personal, and includes competence in problem solving and application of knowledge to relevant real life problems.” Emaginos is committed to creating that learning environment. While the company believes that America’s K-12 public schools are a national treasure, it also points to numerous studies that all reach the same conclusion – the K-12 public education system in this country is broken and cannot be fixed. The solution, however, isn’t as drastic as it may sound. The game-changing Emaginos model uses existing facilities, teachers, and administers and can be implemented within existing budgets using existing proven best practices. So what’s new? Just about everything else. Emaginos begins by transforming an initial school within the district to a charter school as a model for the transformation. The charter model implements the Emaginos Discovery Learning System (“DLS”) that outlines a systemic transformation from the current teacher-centered model to a K-12 public education system that fosters and supports a student’s desire to learn. After the model is successful in the charter school, the lessons learned in transforming the initial school are used to continue the change throughout the rest of the school district. Dedicated to transforming K-12 public schools to a model composed of integrated proven best practices, Emaginos opposes replacing public schools with charter schools or damaging public schools by draining resources through vouchers or school choice programs. Emaginos firmly believes in restoring the concept of the neighborhood schools as the center of the community. “It is time to stop wasting money patching and repairing a system that is obsolete,” states the Emaginos website. “It is time to transform the system, integrating the best practices available while discarding the sacred cows that have held back true reform.” It is time for Emaginos. For more information, visit the company’s website at www.Emaginos.com. NOTE TO INVESTORS: The latest news and updates relating to Emaginos are available in the company’s newsroom at https://ibn.fm/Emaginos

• Brain Scientific was featured in Neoscope, a publication of Futurism, a media company concentrating on the scientific and technological advances for the future
• Article details e-tattoo, BRSF’s solution that can capture big data in real-time about brain activity with possible applications in epileptic seizure predictions
• E-tattoo could prove invaluable to medical researchers studying neurological conditions or even developers building brain-computer interfaces for mind-controlled electronics, video games

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has been featured in Neoscope as a company that champions cutting-edge research pushing the boundaries of what is possible in the brain diagnostics field (https://ibn.fm/IOD55). Neoscope is the publication of Futurism, a New York City-based media company concentrating on the scientific and technological advances for the future. The article details Brain Scientific’s e-tattoo technology — a series of tiny electrodes stitched beneath the skin that can get a clear reading of neural signals in real-time. Although the e-tattoo could be used to develop brain-computer interfaces for virtual reality experiences or games controlled by neural signals or for mind-controlled electronics, the immediate use of this ground-breaking technology is primarily in the medical field. The feature reports that Brain Scientific is exploring possibilities to use big data collected through e-tattoo to study the neurological precursor of epileptic seizures in patients. Whether there exists a typical pattern of brain waves before seizures occur would be invaluable information for doctors and patients alike. Still, the question remains unresolved so far. The article cites that Brain Scientific’s e-tattoo, however, could be a game-changer. E-tattoo would give researchers access to the wealth of real-time neurological data collected over a long time, something not possible to recreate in a lab. “We are trying to predict when a seizure can happen,” Boris Goldstein, co-founder and executive chairman of Brain Scientific, told Futurism. “It is too still premature to say what the results will be, but these are more or less our goals: Just to predict when the seizure will happen so you can get medicine that might prevent it.” Neoscope continues with a detailed description of the e-tattoo in the piece. E-tattoo is virtually invisible — electrodes the size of a hair are embedded under the skin, while a microEEG, as small as a postage stamp, is hidden behind the patient’s ear. The article goes on to feature the graphene band, another brain diagnostics solution the Brain Scientific is currently developing. It can be imprinted onto the head like a “temporary tattoo” that can also read the same neural signals through the skin. Although less invasive and easier to remove, it will probably not provide the same level of access to the user’s brainwaves. It can be washed off with a special solvent instead of needing to be removed by a doctor, but herein lies its biggest flaw, too. Because it is not placed deep into the skin, it would not capture real signals only, which means that the data it collects would likely be affected by noise. With a wealth of neural signals collected in real-time, e-tattoo could prove invaluable to medical researchers studying neurological conditions and tech developers of the future building brain-computer interfaces. The article concludes that whatever findings emerge from the epilepsy research, this immense amount of neurological data is a real treasure trove bound to reveal new, to this day, unknown or unresolved secrets of the human brain. Redefining what is possible, Brain Scientific is determined to tackle critical challenges in neurology by bringing these breakthrough findings to patient’s neurological care. For more information, visit the Company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Nextech recently announced preliminary Q1 2021 results in which it reported over 200% increases in both revenue and gross profits compared to a similar period last year
• Nextech is targeting revenue of between CA$50-$60 million for FY 2021, and the company intends to reach this target by launching a number of new products
• Nextech had already launched some of the planned products in Q1 2021
• The preliminary results are likely indications of the influence of the fulfilled launches and that the company is on course to realize its targets

In a presentation to investors during the Virtual Investor Conferences earlier this year, Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF) founder and CEO Evan Gappelberg intimated that the company was targeting revenue of CA$50-60 million for FY2021. To achieve this target, Evan delineated “catalysts” in the form of planned launches that would include an ad network, new major brands for its e-commerce division, new augmented reality (“AR”) technology that facilitates holoportation and a standalone AR room product (https://ibn.fm/xgz5c). As at the end of the first quarter of 2021, on March 31, the company had already launched its Ad Network and a holoportation feature on its AiR Show app that beams a live human hologram. Perhaps indicative of the influence these launches have already had on the company, the prevailing momentum towards realizing its targets for the full-year 2021, as well as the existing room for even more growth, Nextech reported promising preliminary Q1 2021 financial results on April 29 (https://ibn.fm/nKFY6). Per the unaudited results, Nextech’s estimated Q1 2021 revenue is up nearly 208% to between $7.5-$7.7 million compared to revenue of $2.5 million for a similar period in 2020. Further, the company’s gross profits for the three months ended March 31, 2021, are estimated at between $4.1-$4.3 million, representing an increase of 193-207% compared to the $1.4 million reported for Q1 2020. The preliminary value of total bookings for Q1 2021 stands at $2.2 million. “We are unique in that we are diversified with four fast-growing businesses, which all have a red thread of augmented reality connecting them, creating a major product differentiation and competitive advantage,” said Evan in a statement accompanying the preliminary results announcement. “We are strategically positioned with our AR, e-commerce and Inferno AR video conferencing and virtual experience business units to thrive in this new economy being led by a digital transformation across technology.” Evan observed that the present age had presented more business opportunities for sectors in which Nextech has a foothold, namely virtual conferences, virtual events, e-commerce, AR and virtual learning. This effectively means that the company should benefit significantly by capitalizing on these opportunities through the coming period. NTAR foresees the strong business trends in each of these sectors continuing through the second quarter of 2021 and beyond, underscoring that the subsequent reporting periods will possibly witness equally significant financial results and growths. Nextech expects to release the audited financial statements on or around May 13, 2021. For more information, visit the company’s website at www.NextechAR.com. NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF

• PRPI’s XYO Mechanical Balancing Technology delivers energy-efficient, high-performance solutions for rotating equipment, machinery, and devices
• XYO harnesses rotor displacement energy to move compensating masses, correct for imbalance, reduce vibration
• The technology can be customized for virtually anything that rotates

When things that rotate become unbalanced, havoc ensues. From washing machines and boat propellers to engine fans and drive shafts, performance is hampered — and sometimes even destroyed — when rotation goes off kilter. World experts in vibration reduction, Perpetual Industries (OTC: PRPI) solves the problem with its proprietary XYO Mechanical Balancing Technology. “The XYO Mechanical Balancing Technology delivers energy-efficient, high-performance solutions for rotating equipment, machinery, and devices,” said PRPI president and CEO Brent Bedford (https://ibn.fm/Dz9qa). “XYO is a proprietary technology, and the market potential is virtually limitless.” PRPI’s award-winning tech (XYO Mechanical Balancing Technology received a gold medal at the International Exhibition of Inventions in Switzerland) harnesses rotor displacement energy to move compensating masses and automatically corrects for the imbalance and reduces vibration. Operating under the principle that everything that rotates needs to be balanced, PRPI’s XYO Balancing Technology has been tried and tested in an array of settings, with impressive results, including the following:

• automotive driveshafts, 91% reduction of vibration
• washing machines, 89% reduction of vibration
• refrigeration compressors, 85% reduction of vibration
• industrial fans, 83% reduction of vibration
• engine fans, 80% reduction of vibration
• professional angle grinders, 63% reduction of vibration
• boat propellers, 47% reduction of vibration
• electric trolling motors, 41% reduction of vibration

With unlimited application possibilities, XYO Mechanical Balancing Technology can be customized for virtually anything that rotates, resulting in a more energy-efficient product and outcome. For instance, when the technology was tested on washing machines, in addition to the 89% reduction of vibration, the spin speed was increased by 29 RPMs, power consumption decreased by 43%, and noise levels went down by 11.3 decibels. In addition, the technology improved longevity, decreased mechanical wear, and lowered warranty repair. Similar results are being recorded in engineer reports wherever XYO technology is being tested and used (https://ibn.fm/L9QHQ). In addition to decreased vibrations, PRPI’s proprietary tech delivers decreased power consumption, reduces mechanical wear and tear, lowers noise emissions, optimizes operational efficiency, and cuts maintenance costs. Perpetual Industries is an incubator for the development of new and innovative energy-efficient technologies. The company’s mission is to “perpetuate industry” by bringing value-added technologies to market. The company is expanding its expertise and knowledge of energy-efficient technology by developing low-cost, green-energy-powered solutions for a variety of industries while continuing its research, development, and commercialization of the XYO Technology in key applications. For more information, visit the company’s website at www.PerpetualIndustries.com. NOTE TO INVESTORS: The latest news and updates relating to PRPI are available in the company’s newsroom at https://ibn.fm/PRPI

• Tryp Therapeutics is a pharmaceutical developer working to produce novel bioscience solutions, including a synthetic psychedelic drug candidate for treating some chronic pain and eating disorders
• Tryp CEO Greg McKee appeared on the Entrepreneur Magazine podcast “Action and Ambition” earlier this month to discuss lessons learned on his road to success and to highlight the company’s purpose in developing treatments for helping people be more whole
• Psychedelic drug therapies have been developing a growing fanbase, highlighted by California state Sen. Scott Wiener’s legislation this year seeking to decriminalize hallucinogenics
• McKee noted that many military personnel are using psychedelics in an effort to “reset” themselves following combat duty-related traumas, such as PTSD and phantom limb pain

The “Back to the Future” movie series mined comedic outcomes of time travel in its adventures, but the bioscience pharmaceutical developers at Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) are entirely serious in their efforts to bring back for future use psychedelic substances that once were used for varying purposes ranging from religious healing to recreational adventurism. “Obviously, psychedelics have been around for a long time,” Tryp CEO Greg McKee said during a podcast episode this month for Entrepreneur Magazine’s “Action and Ambition” show, which invites successful business executives to share their stories and lessons learned on the road to success (https://ibn.fm/DpiHh). “[Psychedelics] were used recreationally years back,” McKee continued. “Johns Hopkins has done a pilot work clinically to show that there’s activity in [using them to treat] depression and PTSD and there’s a lot of other academic institutions that are showing there’s probably activity and potentially utility in a whole bunch of other areas like neuropathic pain and eating disorders for example, right? So there’s probably…seven to 10-plus different therapeutic indications.” Tryp was founded in 2019 and is making a name for itself by mining the barely emerging psychedelics-for-medicinal-purposes sector of the lifestyle and wellness market as it advances two potential drug platforms — the mushroom-based psychedelic psilocybin for treating fibromyalgia, eating disorders and chronic pain conditions; and the cancerous tumor-inhibiting drug razoxane for treating soft tissue sarcomas. Tryp’s psilocybin product is a synthetic drug candidate named TRP-8802, administered orally. A 2018 study funded by the Heffter Research Institute and published in Science Direct found that there is low abuse and no physical dependence potential for psilocybin when used medicinally, concluding that the federal drug classification for it should be reduced from Schedule I to “no more restrictively than Schedule IV” (https://ibn.fm/40tss). Efforts to legalize psychedelic therapeutics along the same legislative pathway taken by cannabis advocates have found a growing number of supporters in recent years, including California state Sen. Scott Wiener, who has introduced a bill this year that would decriminalize select hallucinogens, including psilocybin (https://ibn.fm/ukONR). McKee told podcast host Phillip Lanos that one of his first introductions to the potential benefits of psychedelics arose from his acquaintance with some Navy Seals in Southern California who use 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), also known as O-methyl-bufotenin (https://ibn.fm/8bkWO). “And they swear by it,” McKee said, noting many military personnel in the area suffer from combat-related traumas and use the psychedelic for “a reset.” McKee said that his company’s formulation is different from 5-MeO-DMT but regardless of the chemical makeup, his hope is that psychedelics with potential therapeutic uses can end of gaining more mainstream use. “I’m really excited,” he told Lanos. “Anything that we can do…to enhance performance, or to take away pain, get people to reach their potential, I think it’s incredible and that’s one of the great things we can do in the biotech space.” For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF